Investorideas.com

Investorideas.com
Breaking News

Investorideas.com newswire

Thursday, June 25, 2015

Medical Technology News; Vycor (OTCQB:VYCO) Announces Commercial Release of Its NovaVision Web Deliverable Therapy Suite

"We are now finally in a position to deliver our therapies to the large numbers of people who suffer vision loss as a result of neurological brain damage as a cost effective and complete therapy solution" - CEO of Vycor

BOCA RATON, Florida - June 25, 2015 (Investorideas.com Newswire) - Vycor Medical, Inc. ("Vycor") (VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced the commercial release of its Internet-delivered therapy suite in the U.S. This therapy suite, consisting of its lead Vision Restoration Therapy (VRT) and its NeuroEyeCoach eye-movement compensation therapy, is delivered directly to patients over the Internet onto their own computers replacing the Company's current "prototype hardware centric" model.

NovaVision has been working to take its VRT therapy prototype and develop it into an affordable, scalable therapy offering that offers broader patient benefits. VRT will going forward be provided alongside NovaVision's NeuroEyeCoach compensatory therapy in one Internet delivered therapy suite. Two things happen when someone suffers from vision related disorders following a stroke or brain injury: there is a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT addresses the restoration of lost vision while NeuroEyeCoach addresses patients' difficulty with their eye movements and their ability to integrate visual information, allowing them to make the most of their remaining vision, The two therapies provided in a suite are therefore highly complementary and ensure broad benefits to NovaVision's patients.

NovaVision is now positioned, for the first time, with the suite of therapies and product offerings to deliver on its strategic vision: to provide a clinically supported, affordable and scalable visual therapy solution offering broad benefits to those suffering visual impairment following neurological damage; and to offer solutions for both patients and physicians alike.

For Patients:
·        VRT and NeuroEyeCoach Therapy Suite. NovaVision will commercially launch this week these two complementary therapies, internet-delivered in a package for $900.
·        NeuroEyeCoach. For patients with visual impairments who are not suitable, for whatever reason, for VRT, NovaVision provides NeuroEyeCoach on its own for $450.

For Physicians:
·        Vision Diagnostic (VIDIT). The diagnostic component of VRT that enables therapists to perform high-resolution visual field tests in less than 10 minutes to screen for visual field deficits.
·        NeuroEyeCoach Pro Center. Enables stroke rehabilitation and other centers to treat patients while in their care, both as in-patient and out-patient.
·        NovaVision and NeuroEyeCoach Pro Physician. Enables physicians to register patients in their clinic who complete the therapy at home, supported by NovaVision but monitored by the physician through a dedicated portal.

VRT is a prescription product and the only FDA cleared therapy (510k) for the restoration of vision loss from neurological damage. VRT is supported by 15 years of clinical research and over 20 studies including a 302 patient study in which notable improvements were seen in 70% of the patients. NeuroEyeCoach is also clinically supported being based on research that has been the subject of 14 clinical studies on a total of 591 patients and has FDA registration.

Commenting on the Company's announcement, Peter Zachariou, CEO of Vycor, stated: "This has been a long time coming and has entailed an enormous amount of work from both our employees but also our scientific advisors and is a key milestone for NovaVision. We are now finally in a position to deliver our therapies to the large numbers of people who suffer vision loss as a result of neurological brain damage as a cost effective and complete therapy solution. I am convinced that this new therapy suite is the most robust, affordable and complete commercially available visual therapy solution targeted at this type of vision loss.
This also represents the final step in moving NovaVision from being a development company to one focused on commercializing its unique suite of products. I would urge anyone who has had a stroke or brain injury and suffers from a visual disorder to contact us, we have numerous testimonials of patients for whom these therapies have literally changed their lives".

There are approximately 8m stroke survivors in the U.S. with 795,000 strokes a year, and approximately 1.5m suffering some sort of Traumatic Brain Injury (TBI) annually; up to 30% of these suffer a resultant visual impairment, up to 20% permanently. In all, around 2.8 million Americans suffer from this type of vision impairment, which is largely unaddressed by the rehabilitation system. The impact on their daily lives is dramatic, and is the difference between a person being able to be home alone, cross the road unaided, drive, shop or read. The new therapy suite is targeted at this largely underserved group of people.

For an overview of NovaVision see NovaVision Video.


About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly traded company (VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical's ViewSite(TM) Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in Brazil, India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company's proprietary Visual Restoration Therapy(R) (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any Physician. VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed a therapy called NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to VRT(TM). The two therapies address different visual disabilities each of which results from neurologically-induced vision loss - a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.comwww.vycorvbas.com or www.novavision.com.

Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Vycor Medical, Inc. Contacts:
6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

SOURCE: Vycor Medical, Inc.

For more information on VYCO on Investorideas, please visit: http://www.investorideas.com/CO/VYCO/


Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Vycor Medical Inc. (VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media and news distribution: Five thousand per month, one month with option to renew.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.





Post a Comment